Padcev received accelerated approval for the treatment of locally advanced or metastatic urothelial cancer announced on Dec. 18, 2019.It specifically targets the cell adhesion molecule Nectin-4, which is highly expressed in urothelial cancers. “Antibody-drug conjugates are strategic tools in the targeted treatment of cancer. These conjugates combine the ability of monoclonal antibodies to target specific […]
